Marios C. Yiannakas1, Ratthaporn Boonsuth1, Carmen Tur1,2, Marco Battiston1, Francesco Grussu1,3, Rebecca S. Samson1, Torben Schneider4, Masami Yoneyama5, Ferran Prados1,6,7, Sara Collorone1, Rosanna Cortese1, Olga Ciccarelli1, and Claudia A. M. Gandini Wheeler-Kingshott1,8,9
1NMR Research Unit, Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Fuculty of Brain Sciences, University College London, London, United Kingdom, 2Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d’Hebron Institute of Research, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain, 3Radiomics Group, Vall d’Hebron Institute of Oncology, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain, 4Philips Healthcare, Surrey, Guildford, United Kingdom, 5Philips Japan, Minatoku, Tokyo, Japan, 6Centre for Medical Image Computing, Medical Physics and Biomedical Engineering, University College London, London, United Kingdom, 7Universitat Oberta de Catalunya, Barcelona, Spain, 8Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy, 9Brain Connectivity Research Centre, IRCCS Mondino Foundation, Pavia, Italy
Synopsis
Whilst multiple sclerosis (MS) is thought to be a disease of the central
nervous system, evidence from neuropathological investigations has demonstrated
that the peripheral nervous system (PNS) can also be affected in MS, with demyelination
and axonal degeneration being the main pathophysiological mechanisms involved. In
this study, PNS damage is assessed in
vivo at proximal (lumbar plexus) and distal (sciatic nerve) anatomical
locations in people with relapsing-remitting MS and healthy controls using
magnetisation transfer ratio (MTR). Results demonstrate significantly reduced
MTR values at distal anatomical locations, however no relationship is
identified between these changes and clinical scores of disability.
INTRODUCTION
Peripheral nervous system (PNS) involvement in multiple sclerosis (MS) is
an area that has received very little attention over the years, despite the evidence
from neuropathological and biopsy reports confirming the presence of PNS damage
at both proximal and distal anatomical locations in people with MS1-4.
Given the discrepancies observed frequently between clinical symptoms and
damage to the central nervous system (CNS), understanding the mechanisms of PNS
damage and the interdependencies with CNS pathology could be invaluable in
addressing this gap in knowledge. In this study, we investigated the lumbar
plexus and the sciatic nerve of people with relapsing-remitting MS (RRMS) and
healthy controls in vivo using magnetisation
transfer ratio (MTR) to determine: a) the presence of PNS damage at proximal
and distal anatomical locations and b) the relationship between MTR measures
and clinical scores of disability.METHOD
1) Participants: Eleven healthy controls (HCs) (mean age 33.6 years, 7 female, range 24-50)
and 15 people with relapsing remitting MS (RRMS) (mean age 38.5 years, 12
female, range 30-56) were recruited for this study. Informed consent was obtained from all participants and the study was
approved by local ethics; 2) Clinical assessments: All people with RRMS
were assessed using the expanded disability status scale (EDSS) by a qualified
neurologist; 3) MRI protocol: A Philips Ingenia CX 3T was used with 28-channel anterior and posterior
coils. For visualisation of the lumbar plexus and the sciatic nerve, the 3D
SHINKEI sequence was used in the coronal plane5,6. For the lumbar
plexus, MTR imaging was performed in the coronal plane using
identical scan geometry to the 3D SHINKEI acquisition to obtain mean MTR values
in the proximal L2-L5 segments. For the sciatic nerve, the upper 1/3 of the
thigh was imaged using high-resolution fat-suppressed T2-weighted and
MTR acquisitions in
the axial plane; details of the MRI acquisition and analysis protocol were reported
previously7; 4) Image
analysis: Image segmentation was performed manually in FSLview (http://www.fmrib.ox.ac.uk/fsl/).
For the lumbar plexus, each lumbar segment (L2-L5) was manually segmented on
the 3D SHINKEI images, with separate binary masks created for the
preganglionic, ganglionic and post ganglionic regions (Figure 1). The sciatic
nerve was segmented manually on fat-suppressed T2-weighted images (Figure 2); 5) Statistical analysis: Statistical analysis was performed using STATA/SE 14.2 (StataCorp, College
Station, TX). Linear regression models (adjusting for age and gender) were used
to: a) identify differences in MTR values between HCs and people with RRMS at each
anatomical location; b) identify relationships between MTR measures and
clinical scores of disability (EDSS).RESULTS
In HCs, mean (±SD)
MTR in all lumbar segments combined (L2-L5) was 28.0 (±5.6) and in people with
RRMS was 28.8 (±5.2); this difference was not statistically significant (p=0.43).
In addition, no statistically significant differences in MTR values were
identified between the groups in the preganglionic, ganglionic and
postganglionic regions (Figure 3). In the sciatic nerve, mean (±SD) MTR in HCs
was 35.0 (±3.9) and in people with RRMS was 32.4 (±4.4); this difference was
statistically significant (p=0.027) (Figure 4). Figure 5 shows the summary of
all the MTR measurement in HCs and people with RRMS. The mean EDSS of the group
was 1.7. No correlations were identified between the MTR measures and clinical
scores of disability (EDSS) at any of the anatomical locations.DISCUSSION AND CONCLUSION
In this study we have demonstrated significant changes in MTR values in the
sciatic nerve of people with RRMS as compared to HCs, but no changes were
identified in the lumbar plexus. This finding demonstrates that pathological
changes in myelin content can be present at distal locations of the PNS in
people with RRMS, but maybe independent of changes at more proximal locations
of the PNS. Furthermore, no relationship between the MTR measures in the PNS
and clinical scores of disability (EDSS) were identified in this cohort of
people with RRMS suggesting that more work is needed in the future to better understand
the role of the PNS in explaining physical disability in MS.Acknowledgements
The UK MS Society and the UCL-UCLH Biomedical
Research Centre for ongoing support.
CGWK receives
funding from the UK MS Society (#77), Wings for Life (#169111), Horizon2020
(CDS-QUAMRI, #634541), BRC (#BRC704/CAP/CGW). FP is a non-clinical Postdoctoral
Guarantors of Brain fellow. This project has received funding under the
European Union’s Horizon 2020 research and innovation programme under grant
agreement No. 634541 and from the Engineering and Physical Sciences Research
Council (EPSRC EP/R006032/1), funding FG. FG is currently supported by the
investigator-initiated PREdICT study at the Vall d'Hebron Institute of Oncology
(Barcelona), funded by AstraZeneca. CT receives the support of a fellowship
from ”la Caixa” Foundation (ID 100010434). The fellowship code is
LCF/BQ/PI20/11760008.References
-
Hasson J, Terry R.D Zimmerman H.M. Peripheral neuropathy in multiple sclerosis.
Neurology. 1958; 8(7):503-10.
- Miglietta O, Lowenthal M. A study of peripheral nerve involvement in fifty-four
patients with multiple sclerosis. Arch Phys Med Rehabil. 1961;42:573-8.
- Pollock M, Calder C, Allpress S. Peripheral nerve abnormality in multiple
sclerosis. Ann Neurol. 1977;2(1):41-8.
- Schoene W.C, Carpenter S, Behan P.O, et al. ‘Onion bulb’ formations in the
central nervous system in association with multiple sclerosis and hypertrophic
polyneuropathy. 1977;100(4):755-73.
- Yoneyama
M, Takahara T, Kwee T.C, et al. Rapid high resolution MR neurography with a
diffusion-weighted pre-pulse, Magn. Reson. Med. Sci. 2013;12(2):111–119.
- Kasper
J.M, Wadhwa V, Scott K.M, et al. SHINKEI-a novel 3D isotropic MR neurography
technique: technical advantages over 3DIRTSE-based imaging, Eur. Radiol.
2015;25(6):1672–1677.
- Yiannakas MC, Battiston M, Grussu F, et al. A pilot in vivo investigation of
peripheral nerve damage in multiple sclerosis using magnetisation transfer
ratio. ISMRM 2020, 1401.